CAJ | 학술논문

目的：探讨阿托伐他汀对终末期肾脏病患者脑钠肽及心功能的影响。方法选取本院2011年10月～2013年10月诊治的终末期肾脏病患者106例，根据治疗方案分为两组，53例患者实施常规治疗为对照组，53例患者加用阿托伐他汀为观察组，疗程12周。于治疗前后使用彩色多普勒超声检测患者的左室射血分数和左室舒张末期内径，比较两组患者治疗前后的脑钠肽水平和心功能指标，分析两组患者的不良反应情况。结果治疗后，两组患者脑钠肽、左室舒张末期内径均显著减小，而左室射血分数显著增加。观察组患者脑钠肽、左室舒张末期内径均明显小于对照组，观察组患者左室射血分数明显高于对照组，差异均有统计学意义（P＜0.05）。观察组患者不良反应发生率高于对照组，差异无统计学意义（P＞0.05）。结论阿托伐他汀可明显改善终末期肾脏病患者的心功能，降低脑钠肽水平，不良反应少且安全性高，值得临床推广使用。
목적：탐토아탁벌타정대종말기신장병환자뇌납태급심공능적영향。방법선취본원2011년10월～2013년10월진치적종말기신장병환자106례，근거치료방안분위량조，53례환자실시상규치료위대조조，53례환자가용아탁벌타정위관찰조，료정12주。우치료전후사용채색다보륵초성검측환자적좌실사혈분수화좌실서장말기내경，비교량조환자치료전후적뇌납태수평화심공능지표，분석량조환자적불량반응정황。결과치료후，량조환자뇌납태、좌실서장말기내경균현저감소，이좌실사혈분수현저증가。관찰조환자뇌납태、좌실서장말기내경균명현소우대조조，관찰조환자좌실사혈분수명현고우대조조，차이균유통계학의의（P＜0.05）。관찰조환자불량반응발생솔고우대조조，차이무통계학의의（P＞0.05）。결론아탁벌타정가명현개선종말기신장병환자적심공능，강저뇌납태수평，불량반응소차안전성고，치득림상추엄사용。
Objective To investigate influence of atorvastatin on brain natriuretic peptide and heart function in patients with end stage renal disease. Methods 106 patients with end stage renal disease were selected in hospital from October 2011 to October 2013. According to treatment, patients were divided into two groups.53 patients received routine treatment as control group.53 patients combined with atorvastatin as observation group.Course of treatment was 12 weeks. Left ventricular ejection fraction and left ventricular end diastolic diameter were detected by color doppler ultrasound before and after treatment. Brain natriuretic peptide and cardiac function indexes were compared between two groups before and after treatment. Adverse reactions were analyzed in two groups. Results After treatment, brain natriuretic peptide and left ventricular end diastolic diameter significantly reduced while left ventricular ejection fraction significantly increased in two groups. Brain natriuretic peptide and left ventricular end diastolic diameter in observation group were significantly less than control group. Left ventricular ejection fraction in observation group was significantly higher than control group. Differences were statistically significant(P<0.05). Incidence of adverse reactions in observation group was higher than control group. Difference was not statistically significant(P > 0.05). Conclusion Atorvastatin can significantly improve heart function of patients with end stage renal disease, which can also reduce brain natriuretic peptide. Atorvastatin has less adverse reactions and high safety, which is worthy of clinical use.